QCG
DYN icon

Quadrant Capital Group’s Dyne Therapeutics DYN Stock Holding History

Quadrant Capital Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67
Closed -$1.22K – 1629
2026
Q1 		$1.22K Hold
67
– – ﹤0.01% 2564
2025
Q4 		$1.31K Hold
67
– – ﹤0.01% 2572
2025
Q3 		$848 Buy
+67
New +$764 ﹤0.01% 2570
2025
Q2 		– Sell
-231
Closed -$2.42K – 1712
2025
Q1 		$2.42K Hold
231
– – ﹤0.01% 2481
2024
Q4 		$5.44K Hold
231
– – ﹤0.01% 2280
2024
Q3 		$8.3K Hold
231
– – ﹤0.01% 2193
2024
Q2 		$8.15K Hold
231
– – ﹤0.01% 2180
2024
Q1 		$6.56K Hold
231
– – ﹤0.01% 2245
2023
Q4 		$3.07K Buy
+231
New +$2.26K ﹤0.01% 2392

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quadrant Capital Group's DYN Position: Q2 2026 in Review

Quadrant Capital Group sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 67 shares — an estimated $1.22K sold.

Quadrant Capital Group first reported a position in DYN in Q4 2023 and held it in 9 quarters. The position peaked at $8.3K in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Quadrant Capital Group reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 67 Dyne Therapeutics shares in Q2 2026, an estimated $1.22K.
  • Quadrant Capital Group first reported a position in Dyne Therapeutics in Q4 2023 and held it in 9 quarters.
  • Quadrant Capital Group's Dyne Therapeutics position peaked at $8.3K in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.